Pfizer gets early FTC clearance for Metsera acquisition

Pfizer Inc. (NYSE: PFE) announced that the U.S. Federal Trade Commission granted early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act for its pending acquisition of Metsera (NASDAQ: MTSR).

The FTC clearance satisfies the regulatory review requirements for the previously announced acquisition. The original waiting period was set to expire on November 7.

The information is based on a press release statement from Pfizer.

You May Also Be Interested In

• HII targets 15% shipbuilding throughput increase for U.S. Navy in 2026
• Alpha Compute reports $1.57M monthly cash flow and $1.5B pipeline
• RBC Capital Downgrades Spire Healthcare (SPI:LN) (SRRHF) to Sector Perform